DV
Dividend Vision

HIND — Vyome Holdings, Inc.

Vyome Holdings, Inc. (HIND)

Total return is -100.0% over the past 9.9 years, 420.3 points behind SPY at 320.3%. Its deepest 1-year drawdown was 87.9%.

Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company developing therapeutic products for immuno-inflammatory and rare diseases, with lead candidates including VT-1953 (a topical gel for bacterial conjunctivitis and inflammatory acne) and VT-1908 (an eye drop for immunoinflammatory eye conditions), along with antifungal products using its molecular replacement therapy platform. The company does not currently distribute to shareholders. Vyome appeals to investors seeking exposure to early-stage biopharmaceutical development rather than current income, with returns dependent on the success of its clinical trials and product commercialization.

HIND key facts

Asset type
Stock
Asset class
Equity
Inception date
10/06/2016
Last close
$2.18
Market cap
$15,089,836
Average volume
6140.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.56